Background Several studies have investigated the relationship between psoriasis and
adverse cardiovascular outcomes. Previous meta-analyses have shown psoriasis to be a …

In addition to being recognized as a chronic inflammatory disease that manifests in the skin,
psoriasis is increasingly understood to be a systemic disease that causes immune …

Objective—Interleukin (IL)-17A is regarded as an important cytokine to drive psoriasis, an
inflammatory skin disease marked by increased cardiovascular mortality. We aimed to test …

Background An overview of mortality risk associated with psoriasis is lacking. Objective To
perform a systematic review and meta-analysis of mortality risk in psoriasis. Methods We …

Psoriasis is associated with an increased risk of atherosclerosis. Endothelial dysfunction is
the critical early step in the process of atherogenesis, and it is commonly investigated by …

Aims Psoriasis is a common inflammatory disease that is associated with increased risk of
cardiovascular disease, including myocardial infarction. Heart failure (HF) is independently …

Background There is limited information about mortality rates among patients with psoriasis
and psoriatic arthritis (PsA) in North America and their change over the past 2 decades …

Psoriasis, an autoimmune inflammatory disease, with its most common coexisting condition,
psoriatic arthritis, seem to be more than just a local skin or joint disease, as evidence has …

Evidence suggests that psoriasis together with other cardiovascular (CV) risk factors is
associated with increased vascular morbidity, but it is not clear whether psoriasis is an …

Risankizumab is a selective, humanized immunoglobulin G1 (IgG1) monoclonal anti-body
directed against interleukin (IL)-23 protein. The therapeutic indication of risankizumab is …